市场概况

The global market for psoriatic arthritis treatment is projected to reach USD 12.72 十亿 2029, growing at a CAGR of 6.1% from USD 8.27 十亿 2022. Psoriatic arthritis is a chronic inflammatory rheumatic disease that affects up to 30% of psoriasis patients aged 30 到 60. It is more common in women. The exact cause is unknown, but family history and certain risk factors play a role. Diagnosis involves imaging techniques and symptom evaluation. Treatment options include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, 生物制剂, and emerging therapies. The market is driven by the introduction of new drugs and the demand for improved treatments. IL inhibitors and oral JAK inhibitors show promise. The market has over 25 assets in development, with many in Phase III trials. The introduction of novel therapies will fuel market growth. Targeting inflammatory pathways beyond TNF, such as IL-23/IL-17, has proven effective. Technological advancements are expected to enhance interventions and outcomes in the future.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global psoriatic arthritis market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, including drug class, disease type, gender type, 年龄阶层, severity type, 和地理.
Drug class: interleukin inhibitors, NSAIDs, TNF inhibitors, 其他的
Disease type: spondylitis, dactylitis, enthesitis
Gender: 男人, 女性
年龄阶层: 50 years and below, 50 years and above
Severity type: moderate, mild, severe

按地理位置细分
北美 – 美国
Europe – Germany, 法国, 英国, 意大利, 西班牙
亚太地区 – 中国, 日本

TNF-Alpha inhibitors dominate the global psoriatic arthritis treatment market but the fastest growth is expected in interleukin inhibitors. Approvals of drugs like Skyrizi and Cosentyx will drive the market. Women make up a significant portion of the market due to increased risk. Enthesitis holds a significant share but Dactylitis will grow the fastest. Individuals below 50 will make up a substantial portion. Mild form is significant but moderate form will grow the fastest. The United States dominates the market due to affordability, knowledge, 和技术. Germany will experience rapid growth due to healthcare access and awareness. Biosimilars in China and Japan will bring changes. China has the highest number of cases, followed by Spain and the U.K. PsA prevalence is increasing in the European Union.

竞争格局

Major players in the global psoriatic arthritis treatment market include AbbVie Inc, 约翰逊 & 约翰逊, Takeda Pharmaceutical Company Limited, Biogen Inc, UCB SA, Amgen Inc., 百时美施贵宝公司, 辉瑞公司, Eli Lilly and Company, and Novartis AG. These companies are employing strategies such as collaborations, 收购, geographic expansion, research and development, and manufacturing novel drugs to strengthen their product portfolios and compete in the market. Other notable players include Bausch Health Companies Inc., Biocad Biopharmaceutical Co., Bio-Thera Solutions, 有限公司, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., 有限公司, Meiji Holdings Co., 有限公司, 太阳制药工业有限公司, 除其他外. These players prioritize research and development to develop advanced psoriatic drugs and maintain their industry position.

报告范围

To analyze and forecast the market size of the global psoriatic arthritis market.
To classify and forecast the global psoriatic arthritis market based on drug class, disease type, gender, 年龄阶层, severity type, 地理.
To identify drivers and challenges for the global psoriatic arthritis market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global psoriatic arthritis market.
To identify and analyze the profile of leading players operating in the global psoriatic arthritis market.

为什么选择这份报告

Gain a reliable outlook of the global psoriatic arthritis market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.